IPO Boutique Research, Color & More Information for Subscribers
While IPO issuance up to this point have been slower than last year, the underwriters have not been afraid to bring out follow-on offerings. A total of 25 secondary’s were priced for the week of February 23rd which totaled in the multi-billions including a record-breaking offering from Actavis (NYSE: ACT). “Based upon the lack of[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Concho Resources Symbol: CXO Price: Last trade $112.93 Trade Date: 2/27 Shares: 5.6 million Underwriter(s) BofA Merrill Lynch Rating=Subscription Needed Company:[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Lion Biotechnologies, Inc. Symbol: LBIO Price: Last trade $9.30 Trade Date: 2/26 Shares: 5.9 million Underwriter(s) Jefferies, Cowen & Co., Piper[…]
Who’s getting giddy about $GDDY?
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: American Tower Corporation Symbol: AMT Price: Last trade $97.33 Trade Date: 2/26 Shares: 23.5 million Underwriter(s) Goldman Sachs, BofA Merrill Lynch,[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: QTS Realty Trust, Inc. Symbol: QTS Price: Last trade $37.65 Trade Date: 2/25 Shares: 8.7 million Underwriter(s) Jefferies, BofA Merrill Lynch,[…]
This past week two IPOs debuted, zero updated terms and six new deals filed. It was week that produced very little fanfare as the deals that came to market, Inotek Pharmaceuticals (Nasdaq: ITEK) and Check-Cap Limited (Nasdaq: CHEKU) were holdovers from the previous week. Inotek was able to come to market after severely slashing their[…]
Wednesday Wowo Limited (Nasdaq: WOWO) – Axiom is running the deal that is to sell 6.0 million shares at an initial range of $9.00-$11.00. Friday Actavis (Nasdaq: ACT) – The company is pursuing a secondary with concurrent offerings totaling $8.4 billion, comprising $4.2 billion of Ordinary Shares and $4.2 billion of Mandatory Convertible Preferred Shares,[…]
A storyline that developed in December 2014 and has carried over into 2015 thus far is the massive valuations given in rounds of private funding to company’s who eventually intend on going public. We wrote about that issue in January but that same issue is rearing its head again. On Tuesday, the Wall Street Journal[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Actavis Symbol: ACT Price: Last trade $284.00 Trade Date: 2/27 Shares: 14.79 million Underwriter(s) J.P. Morgan, Mizuho Securities, Wells Fargo Securities,[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Neurocrine Biosciences Symbol: NBIX Price: Last trade $37.33 Trade Date: 2/19 Shares: 6 million Underwriter(s) J.P. Morgan, Deutsche Bank Securities Rating=Subscription[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Phillips 66 Partners LP Symbol: PSXP Price: Last trade $78.83 Trade Date: 2/18 Shares: 5.25 million Underwriter(s) Barclays, J.P. Morgan, BofA[…]
This past week five IPOs debuted, one updated terms and seven new deals filed. It was another difficult week for the IPO market as two of the seven new deals planning to come to market were postponed and many others who held-over from prior weeks’ failed to come to market. Among the five who made[…]
Inovalon Holdings, by our account, was more than 20x oversubscribed. The deal was underwritten by some of the best in the business and the demand for the IPO turned into a $6.16 premium above the offering price–or a 23% gain upon opening. But almost immediately, the story changed and ‘INOV’ was suddenly not a desired[…]
Thursday Pricings (Priced Friday AM) Bellerophon Therapeutics (Nasdaq: BLPH) – According to the underwriter, the deal was priced below range and up-sized. ‘BLPH’ prices 5 million shares at $12 and will debut today. Great AJax Corp (NYSE: AJX) – According to the underwriters, the deal was downsized and priced below the $15-$17 range. ‘AJX’ priced[…]
The IPO scene has been relatively weak over the past two weeks. Many deals that have scheduled to come to market have been either postponed or subjected to ‘Day-to-Day’ status while, in theory, management mulls over valuation. However, the weakness will likely be subsided as a pair of deals debut today: Inovalon Holdings (Nasdaq: INOV)[…]
Thursday Expected Pricings Inovalon Holdings (Nasdaq: INOV) – Inovalon Holdings prices IPO $1.00 above the already upwardly-revised range. ‘INOV’ prices 22.2 million shares at $27.00 and will debut on Thursday (2/12). Invitae Corporation (NYSE: NVTA) – Invitae Corp. upsized and priced its IPO above the range. ‘NVTA priced 6.35 million shares at $16.00 and will[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: Transition Therapeutics Inc. Symbol: TTHI Price: Last trade $7.08 Trade Date: 2/12 Shares:[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: CAS Medical Symbol: CASM Price: Last trade $1.29 Trade Date: 2/11 Shares: 6.2[…]
Wednesday Autogenomics (Nasdaq: AGMX) – We have been informed by the underwriter that the deal will likely not price tonight. We will have more information when it becomes available. Sol-Wind Renewable Power (NYSE: SLWD) – The underwriter says that this deal will now price on Wednesday (2/11) in hopes of a Thursday (2/12) debut. Rest[…]